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Letters to the Editorpoints that should be taken into con-
sideration by the authors.
What are the body surface areas of
the patients in both the treated and un-
treated groups? Did any tricuspid ste-
nosis develop after the operation in the
treated group? Is there any residual
gradient or regurgitation in mitral
valve after repair? We think the mor-
tality rate would decrease with contin-
uous blood cardioplegia or perfusion.
In addition, there was residual tri-
cuspid regurgitation detected in 40%
of cases, although an annular diameter
of 22 mmwas reached postoperatively
in the treated group. Was persistence
of pulmonary artery pressure (PAP)
at 32 mm Hg due to residual mitral re-
gurgitation or to mitral pressure gradi-
ent secondary to replacement? Was
this a reason for residual tricuspid re-
gurgitation as well? Could we answer
these questions by dividing the pa-
tients into 2 groups, that is, mitral
valve replacement and mitral valve
repair?
Table 4 shows that mild tricuspid
regurgitation could also be achieved
with a PAP of 32 mm Hg. Do the au-
thors think that an additional tricuspid
annuloplasty technique might be nec-
essary to obtain coaptation even at
a PAP of 32 mm Hg?
Mert Kestelli, MD
Ismail Yurekli, MD
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Izmir Ataturk Education and Research
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Izmir, TurkeyReference
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doi:10.1016/j.jtcvs.2011.09.065Reply to the Editor:
We thank Dr Kestelli and col-
leagues for their comments and am
glad they appreciate our study.The JournalThe 2 groups of patients were
comparable in terms of body surface
area (1.76  0.2 m2 in the untreated
group vs 1.78  0.2 m2 in the treated
group), and no patient showed echo-
cardiographic or clinical signs of tri-
cuspid stenosis (mean gradient, 2.4 
0.6). We follow what Frater pro-
posed1 only because our results are
satisfying. If we had been aware of
an increased gradient across the tri-
cuspid valve, Frater’s concept (tricus-
pid annulus to be reduced to fit
a number 25 size) would have been
abandoned.
We did not include patients with
any problem in the left side that
could cause, by itself, persistence of
functional tricuspid regurgitation
(FTR). ‘‘During follow-up, those pa-
tients who showed any sign of repair
failure, prosthetic malfunction, or se-
vere impairment of left ventricular
function, events that could justify
the development of additional func-
tional tricuspid regurgitation (FTR),
were excluded from the present study
(n ¼15).’’ This sentence is at the
end of the paragraph ‘‘Population’’
(p 308).2
Dr Kestelli and colleagues are con-
cerned about the value of systolic pul-
monary pressure in group T (32 mm
Hg), which seems close to normal to
me. Pulmonary pressure does not nor-
malize in most patients, and we do not
need to advocate residual mitral regur-
gitation or high transmitral gradients
to justify such a mean value. As stated
before, patients who showed one of
these patterns were excluded.
Tricuspid regurgitation (TR) de-
pends on many factors that act at dif-
ferent levels (annulus, leaflets,
ventricle), but we work mainly on
the annulus. Ventricular factors, such
as papillary muscle displacement
with increased chordal tethering, are
not addressed in tricuspid repair for
FTR. For this reason, we have to ac-
cept results that are sometimes not
perfect (do you really think that resid-
ual 1þ TR is a suboptimal result?).
Furthermore, we have to rememberof Thoracic and Cardiovascular Surgethat medical treatment influences
FTR grade.
Excessively forcing the coaptation
of the tricuspid leaflets will not ensure
better results. There is always a com-
promise between the reduction of the
annular size and the increased chordal
tethering related to the movement of
the anterior and posterior leaflets to-
ward the septal leaflet. On the other
hand, the association between annular
size and FTR is not clear. We know
that normal tricuspid annuli do not
avoid the presence of FTR, even
with a non-severe grade.3,4 Sadeghi
and colleagues5 reported 27 patients
with pulmonary thromboembolism,
severe pulmonary hypertension, and
severe TR who underwent surgery
without tricuspid valve annuloplasty.
In 19 patients (70%), the pulmonary
pressure decreased by a mean of 49
mm Hg and TR was reduced to mild.
In the remaining 30% of patients,
TR remained severe and pulmonary
pressure was reduced to 32 mm Hg,
less than in the other group. In both
groups, the annular size remained un-
changed (4-mm reduction between
pre- and postoperative echocardio-
grams) and similar (41 mm in the first
group and 42 mm in the second group
in the postoperative assessment). We
can deduct that, even if the annulus re-
mains dilated, this does not prevent
TR reduction, but the mechanisms re-
lated to right ventricular reverse re-
modeling, after pulmonary artery
pressure reduction of different de-
grees, are more important than the
pure annular size.
In regard to the myocardial protec-
tion strategy, we thank Dr Kestelli
and colleagues for their advice, but,
as far as we know, there is no random-
ized trial that shows any significant
benefit in using continuous blood car-
dioplegia (warm? cold? antegrade?
retrograde?). Early mortality depends
more on the quality of patients under-
going operation (eg, comorbidities,
urgency or emergency, left or right
ventricular function) rather than on
the pure cardioplegic technique.ry c Volume 143, Number 1 253
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